Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.
about
Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture.Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadA contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virusModulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis.Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model.Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferretsTransforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis.Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.Influenza A virus infection kinetics: quantitative data and models.Targets for the induction of protective immunity against influenza a viruses.The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferretsProtection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.Virus-like particles as universal influenza vaccinesVaccination against influenza with recombinant hemagglutinin expressed by Schizochytrium sp. confers protective immunity.An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein.Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs.In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets.Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.History of vaccinationIdentification of novel avian influenza virus derived CD8+ T-cell epitopesCooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity.Biological and protective properties of immune sera directed to the influenza virus neuraminidase.Emerging respiratory viruses: challenges and vaccine strategiesImmunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition.Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel.Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffectiveThe B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin.Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutininContribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response
P2860
Q25257105-3835E257-9B2F-4DE8-BB22-647B223BB4FEQ26783897-C2FA5EAB-EB22-421A-A4F0-A1B48FAB6CEFQ27316330-FDC5D95D-CDBF-4BE7-B713-CD11FC916C42Q30359683-4C933A52-0943-417C-955C-B0C558877FBBQ30359842-0A6FC4EE-3B0D-41D5-9057-3116B17E9BE2Q30382650-A0F8B49D-8262-42A3-991C-892328C1AD87Q30386612-1C6EA358-D7C6-45CA-8A83-1E4DB6611EE4Q30389407-5DC73D27-4EA1-4893-9BBF-22CB163774EBQ30389582-5EF7DB56-D624-4CB6-947E-0AC5CB67CC05Q30392305-05AFEF33-EF94-4566-8830-60CA8AF8AAD9Q30394903-534FCD3B-0021-440C-AC9F-5546CF7519FFQ30397107-99A7F2C0-01A2-45F4-9F71-98C292C52943Q30398031-5402184B-2498-4DAB-A43B-309589DC56A3Q30408100-8D8659E1-1889-4F6A-B34A-B256749F35E5Q30413023-A6C3CF6E-F3A8-48D2-98F5-86E71989000AQ30418452-1A20F075-C5B8-4FB7-8CE6-4B4ED75D822CQ30421558-7AC01E3A-06FC-4E5C-B7C5-0BE143A26A32Q30429880-A8882E59-3FEC-4963-970A-7A384C2F6218Q30571702-F2A92C81-606D-420C-99EF-1BFC35E7EF29Q33582945-7E68C3CF-1DE7-4502-BFB3-750EB2AF0E5AQ33687181-9EC1B348-D0F8-4444-8740-E23BB9073D24Q33782762-A2372BF7-3C45-4C9C-9B30-844B034964D1Q33782919-0CC7287B-8EAF-4BEE-9B78-3DF41DE68798Q33820732-3F15F419-8733-4784-AEA8-ABBC70397637Q33931916-0B724304-9981-4872-8DC7-F7B4DA03D77BQ33990541-E238C5A8-3198-47CE-9AF0-D5403C970D8FQ34098121-0177D145-6391-4D22-B1CA-6914EDBE1899Q34119899-E5BD58BB-1964-413C-A963-2632831A2499Q34182121-F0FA20D6-183C-44DB-9003-F6EDB1EAF947Q34629133-4ADA2D0E-4026-425F-8EC2-5CFE7CDF271AQ34991399-41147794-CB03-47D2-86B8-4F5A0731F9F4Q35070868-023F16C3-B3E2-4D66-92AD-F904B5369F9BQ35109380-A44C663E-CB5C-4625-AB3A-FB27ED58B602Q35408014-3987FF67-2831-4821-9DEE-54FC985B5DA5Q35826733-18B9858C-A0C8-48ED-B17A-133332BC6A02Q35844791-965F73D1-7CBD-47A2-B6AC-E5F9969E0D51Q35845659-2048FFC5-F0F6-43E0-820B-CB6879BE6B8DQ35852069-C2FCCA7B-C36C-451A-9FC2-FEEAA214D37DQ36075789-8EEB2020-E445-4B9B-8F79-C5953677F2F9Q36381178-B3B2B657-B9E3-407D-B20B-CAD4648656D9
P2860
Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Purified influenza virus hemag ...... ypes of immunity to infection.
@en
type
label
Purified influenza virus hemag ...... ypes of immunity to infection.
@en
prefLabel
Purified influenza virus hemag ...... ypes of immunity to infection.
@en
P2093
P2860
P1433
P1476
Purified influenza virus hemag ...... ypes of immunity to infection.
@en
P2093
B E Johansson
D J Bucher
E D Kilbourne
P2860
P304
P407
P577
1989-03-01T00:00:00Z